Sanofi and Blackstone €300 million collaboration to advance multiple myeloma treatment
The investment will advance the development of a subcutaneous Sarclisa…
The investment will advance the development of a subcutaneous Sarclisa (isatuximab) formulation for multiple myeloma (MM) treatment.